Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers

Takayuki Iwamoto, Toyomasa Katagiri, Naoki Niikura, Yuichiro Miyoshi, Mariko Kochi, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Masako Omori, Yutaka Tokuda, Toshiyoshi Fujiwara, Hiroyoshi Doihara, B. Györffy, Junji Matsuoka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers. Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post- Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively). Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed. Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.

Original languageEnglish
Pages (from-to)26122-26128
Number of pages7
JournalOncotarget
Volume8
Issue number16
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Hormones
Breast Neoplasms
Therapeutics
Large-Core Needle Biopsy
Neoadjuvant Therapy
Estrogens
Down-Regulation
Gene Expression

Keywords

  • Breast cancer
  • Genomic marker
  • IHC Ki67
  • Short-term hormone therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Iwamoto, T., Katagiri, T., Niikura, N., Miyoshi, Y., Kochi, M., Nogami, T., ... Matsuoka, J. (2017). Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. Oncotarget, 8(16), 26122-26128. https://doi.org/10.18632/oncotarget.15385

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. / Iwamoto, Takayuki; Katagiri, Toyomasa; Niikura, Naoki; Miyoshi, Yuichiro; Kochi, Mariko; Nogami, Tomohiro; Shien, Tadahiko; Motoki, Takayuki; Taira, Naruto; Omori, Masako; Tokuda, Yutaka; Fujiwara, Toshiyoshi; Doihara, Hiroyoshi; Györffy, B.; Matsuoka, Junji.

In: Oncotarget, Vol. 8, No. 16, 01.01.2017, p. 26122-26128.

Research output: Contribution to journalArticle

Iwamoto, T, Katagiri, T, Niikura, N, Miyoshi, Y, Kochi, M, Nogami, T, Shien, T, Motoki, T, Taira, N, Omori, M, Tokuda, Y, Fujiwara, T, Doihara, H, Györffy, B & Matsuoka, J 2017, 'Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers', Oncotarget, vol. 8, no. 16, pp. 26122-26128. https://doi.org/10.18632/oncotarget.15385
Iwamoto, Takayuki ; Katagiri, Toyomasa ; Niikura, Naoki ; Miyoshi, Yuichiro ; Kochi, Mariko ; Nogami, Tomohiro ; Shien, Tadahiko ; Motoki, Takayuki ; Taira, Naruto ; Omori, Masako ; Tokuda, Yutaka ; Fujiwara, Toshiyoshi ; Doihara, Hiroyoshi ; Györffy, B. ; Matsuoka, Junji. / Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. In: Oncotarget. 2017 ; Vol. 8, No. 16. pp. 26122-26128.
@article{35cba0b0be8d4794b4133859585f14c9,
title = "Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers",
abstract = "Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers. Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post- Ki67 predicted more low-risk cases (83.3{\%}, 25/30) than pre-genomic surrogate signature(GSS) (66.7{\%}: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively). Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed. Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the na{\"i}ve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.",
keywords = "Breast cancer, Genomic marker, IHC Ki67, Short-term hormone therapy",
author = "Takayuki Iwamoto and Toyomasa Katagiri and Naoki Niikura and Yuichiro Miyoshi and Mariko Kochi and Tomohiro Nogami and Tadahiko Shien and Takayuki Motoki and Naruto Taira and Masako Omori and Yutaka Tokuda and Toshiyoshi Fujiwara and Hiroyoshi Doihara and B. Gy{\"o}rffy and Junji Matsuoka",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.15385",
language = "English",
volume = "8",
pages = "26122--26128",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers

AU - Iwamoto, Takayuki

AU - Katagiri, Toyomasa

AU - Niikura, Naoki

AU - Miyoshi, Yuichiro

AU - Kochi, Mariko

AU - Nogami, Tomohiro

AU - Shien, Tadahiko

AU - Motoki, Takayuki

AU - Taira, Naruto

AU - Omori, Masako

AU - Tokuda, Yutaka

AU - Fujiwara, Toshiyoshi

AU - Doihara, Hiroyoshi

AU - Györffy, B.

AU - Matsuoka, Junji

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers. Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post- Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively). Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed. Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.

AB - Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers. Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post- Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively). Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed. Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.

KW - Breast cancer

KW - Genomic marker

KW - IHC Ki67

KW - Short-term hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=85017519613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017519613&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15385

DO - 10.18632/oncotarget.15385

M3 - Article

VL - 8

SP - 26122

EP - 26128

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -